The relationship between inflammation and atrial fibrillation (AF) has recently attracted significant research interest. Epicardial adipose tissue (EAT) contributes to the pathogenesis of AF through its inflammatory, metabolic, and electrophysiological effects and may also influence AF outcomes. Inflammatory cells within EAT release key proinflammatory cytokines, including interleukin (IL)-1β and tumor necrosis factor-α (TNF-α), which promote cardiomyocyte apoptosis and fibrosis. These changes compromise cardiac electrophysiological stability and elevate the risk of arrhythmias. Moreover, increased EAT thickness and volume have been identified as critical biomarkers for AF risk, providing new insights into AF diagnosis and treatment. However, despite compelling evidence of a strong association between EAT and AF, further studies are needed to fully elucidate the mechanisms underlying the role of EAT and assess its potential as a therapeutic target. This review aimed to explore the specific mechanisms of inflammation-related EAT in AF and evaluate the clinical potential of EAT as a biomarker and therapeutic target.
20 September 2024 in Journal of Magnetic Resonance Imaging
The cardiac variant of Fabry disease (FD) has high rates of missed diagnosis and misdiagnosis due to the lack of systemic symptoms. Here, we report a case of a 68-year-old female with delayed-onset FD presenting as concentric left ventricular hypertrophy (LVH) with right bundle branch block, atrial fibrillation, and diastolic dysfunction, which was first presented with coronary artery spasm. Early cardiac-specific signs are crucial for diagnosing this disease due to the lack of extracardiac indications and the late onset of symptoms. This case raises a new red flag that patients with unexplained LVH and its atypical electrocardiographic (ECG) manifestations accompanied by diastolic dysfunction should be considered for FD. We also recommend further refinement of examinations associated with Fabry disease, which will contribute to the early diagnosis and treatment of the disease.
26 June 2026 in Reviews in Cardiovascular Medicine
Bayes syndrome is characterized by advanced interatrial block (A-IAB), which is associated with atrial fibrillation (AF) and ischemic stroke, and has gained widespread attention in recent years. Myocardial fibrosis, particularly atrial fibrosis, is a crucial substrate for the onset of AF and for atrial electricomechanical dysfunction. Growing evidence indicates a bidirectional relationship between Bayes syndrome and myocardial fibrosis. Myocardial fibrosis leads to delayed atrial conduction and the development of interatrial block (IAB), whereas IAB may exacerbate fibrosis through electrophysiological and hemodynamic changes. Several clinical studies have demonstrated that Bayes syndrome independently predicts the occurrence and recurrence of AF, ischemic stroke, and mortality. Imaging modalities, including late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) and echocardiography, enable noninvasive assessment of myocardial fibrotic burden and atrial structural and functional remodeling. Integrating electrocardiographic markers with imaging phenotypes may improve risk stratification, rhythm-monitoring strategies, and clinical decision-making. However, current evidence remains limited in terms of mechanistic elucidation and prospective clinical validation. This review synthesizes mechanistic and imaging evidence linking Bayes syndrome with fibrosis, discusses the clinical implications, and highlights potential targets for anti-fibrotic strategies and stroke prevention. This review also outlines key knowledge gaps and priorities for future longitudinal studies.